Skip to main content

Advertisement

SpringerLink
Log in

Rituximab as the first-line therapy in anti-synthetase syndrome-related interstitial lung disease

  • Review
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Anti-synthetase syndrome (ASS) is an idiopathic inflammatory myopathy (IIM). In comparison to interstitial lung disease (ILD) in polymyositis and dermatomyositis (PM/DM), ILD in ASS is more frequent, has a more aggressive phenotype, a greater involvement of the lungs, and a more rapid onset of pulmonary symptoms. Continuous declines in predicted forced vital capacity (FVC) and dyspnea were the main features of patients who developed end-stage ILD. The severity of ASS at diagnosis dictates when and which immunosuppressant will be started. There is an experience for the usage of RTX in the first, second, and subsequent lines, as well as for reintroduction and salvage therapies. Not all ASS patients will develop severe illness and require intense immunosuppression. Some features associated with poor prognosis include older age, acute or subacute onset, lack of response to steroids, and lower baseline values for FVC and DLCO. Here we hypothesize that RTX should be the first line of treatment for high-risk ILD in ASS to preserve lung function and then maintenance therapy should be continued with the same or another drug depending on the recovery of lung function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Witt LJ, Curran JJ, Strek ME (2016) The diagnosis and treatment of antisynthetase syndrome. Clin Pulm Med 23:218–226. https://doi.org/10.1097/CPM.0000000000000171

    Article  PubMed  PubMed Central  Google Scholar 

  2. Lundberg IE, Tjärnlund A, Bottai M et al (2017) 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955–1964. https://doi.org/10.1136/annrheumdis-2017-211468

    Article  PubMed  Google Scholar 

  3. Betteridge Z, McHugh N (2016) Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 280:8–23. https://doi.org/10.1111/joim.12451

    Article  CAS  PubMed  Google Scholar 

  4. Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA et al (2017) A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology 56:999–1007. https://doi.org/10.1093/rheumatology/kex021

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Shi J, Li S, Yang H et al (2017) Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol 44:1051–1057. https://doi.org/10.3899/jrheum.161480

    Article  CAS  PubMed  Google Scholar 

  6. Wilfong EM, Young-Glazer JJ, Sohn BK et al (2022) Anti-tRNA synthetase syndrome interstitial lung disease: a single center experience. Respir Med 191:106432. https://doi.org/10.1016/j.rmed.2021.106432

    Article  PubMed  Google Scholar 

  7. Trallero-Araguás E, Grau-Junyent JM, Labirua-Iturburu A et al (2016) Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group. Semin Arthritis Rheum 46:225–231. https://doi.org/10.1016/j.semarthrit.2016.03.011

    Article  CAS  PubMed  Google Scholar 

  8. Gasparyan AY, Ayvazyan L, Mukanova U et al (2019) Scientific hypotheses: writing, promoting, and predicting implications. J Korean Med Sci 34:e300. https://doi.org/10.3346/jkms.2019.34.e300

    Article  PubMed  PubMed Central  Google Scholar 

  9. Marie I, Hatron PY, Dominique S et al (2011) Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 63:3439–3447. https://doi.org/10.1002/art.30513

    Article  CAS  PubMed  Google Scholar 

  10. Korsten P, Rademacher J-G, Riedel L et al (2020) Antisynthetase syndrome-associated interstitial lung disease: monitoring of immunosuppressive treatment effects by chest computed tomography. Front Med 7:609595. https://doi.org/10.3389/fmed.2020.609595

    Article  Google Scholar 

  11. American Thoracic Society (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161:646–664. https://doi.org/10.1164/ajrccm.161.2.ats3-00

    Article  Google Scholar 

  12. Waseda Y, Johkoh T, Egashira R et al (2016) Antisynthetase syndrome: pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases. Eur J Radiol 85:1421–1426. https://doi.org/10.1016/j.ejrad.2016.05.012

    Article  PubMed  Google Scholar 

  13. De Zorzi E, Spagnolo P, Cocconcelli E et al (2022) Thoracic involvement in systemic autoimmune rheumatic diseases: pathogenesis and management. Clin Rev Allergy Immunol 63:472–489. https://doi.org/10.1007/s12016-022-08926-0

    Article  PubMed  PubMed Central  Google Scholar 

  14. Doyle TJ, Dhillon N, Madan R et al (2018) Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review. J Rheumatol 45:841–850. https://doi.org/10.3899/jrheum.170541

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Baratella E, Marrocchio C, Cifaldi R et al (2021) Interstitial lung disease in patients with antisynthetase syndrome: a retrospective case series study. Jpn J Radiol 39:40–46. https://doi.org/10.1007/s11604-020-01030-3

    Article  PubMed  Google Scholar 

  16. Ha Y-J, Lee YJ, Kang EH (2018) Lung involvements in rheumatic diseases: update on the epidemiology, pathogenesis, clinical features, and treatment. Biomed Res Int 2018:6930297. https://doi.org/10.1155/2018/6930297

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Debray M-P, Borie R, Revel M-P et al (2015) Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings. Eur J Radiol 84:516–523. https://doi.org/10.1016/j.ejrad.2014.11.026

    Article  PubMed  Google Scholar 

  18. Langlois V, Gillibert A, Uzunhan Y et al (2020) Rituximab and cyclophosphamide in antisynthetase syndrome-related interstitial lung disease: an observational retrospective study. J Rheumatol 47:1678–1686. https://doi.org/10.3899/jrheum.190505

    Article  CAS  PubMed  Google Scholar 

  19. Mehta P, Aggarwal R, Porter JC, Gunawardena H (2022) Management of interstitial lung disease (ILD) in myositis syndromes: a practical guide for clinicians. Best Pract Res Clin Rheumatol 36:101769. https://doi.org/10.1016/j.berh.2022.101769

    Article  PubMed  Google Scholar 

  20. Kurita T, Yasuda S, Oba K et al (2015) The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology 54:39–44. https://doi.org/10.1093/rheumatology/keu166

    Article  CAS  PubMed  Google Scholar 

  21. Kotani T, Takeuchi T, Makino S et al (2011) Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol 30:1021–1028. https://doi.org/10.1007/s10067-011-1713-6

    Article  PubMed  Google Scholar 

  22. Zhao N, Jiang W, Wu H et al (2022) Clinical features, prognostic factors, and survival of patients with antisynthetase syndrome and interstitial lung disease. Front Immunol 13:872615. https://doi.org/10.3389/fimmu.2022.872615

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Li X, Zhou Q, Wu P et al (2022) A prognostic analysis of antisynthetase syndrome-related interstitial lung disease. Int J Rheum Dis 25:1368–1375. https://doi.org/10.1111/1756-185X.14428

    Article  CAS  PubMed  Google Scholar 

  24. Huapaya JA, Silhan L, Pinal-Fernandez I et al (2019) Long-Term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease. Chest 156:896–906. https://doi.org/10.1016/j.chest.2019.05.023

    Article  PubMed  PubMed Central  Google Scholar 

  25. Cassone G, Sebastiani M, Vacchi C et al (2021) Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review. Drugs Context. https://doi.org/10.7573/dic.2020-8-8

    Article  PubMed  PubMed Central  Google Scholar 

  26. Fujisawa T, Hozumi H, Kamiya Y et al (2021) Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: a randomized, open-label trial. Respirology 26:370–377. https://doi.org/10.1111/resp.13978

    Article  PubMed  Google Scholar 

  27. Sharma N, Putman MS, Vij R et al (2017) Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a US cohort. J Rheumatol 44:1612–1618. https://doi.org/10.3899/jrheum.161217

    Article  CAS  PubMed  Google Scholar 

  28. Kourkouni E, Mitsogiannis G, Simopoulou T et al (2019) Interstitial lung disease in anti-synthetase syndrome. Mediterr J Rheumatol 30:186–189. https://doi.org/10.31138/mjr.30.3.186

    Article  PubMed  PubMed Central  Google Scholar 

  29. Keir GJ, Maher TM, Hansell DM et al (2012) Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 40:641–648. https://doi.org/10.1183/09031936.00163911

    Article  CAS  PubMed  Google Scholar 

  30. Keir GJ, Maher TM, Ming D et al (2014) Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 19:353–359. https://doi.org/10.1111/resp.12214

    Article  PubMed  Google Scholar 

  31. Maher TM, Tudor VA, Saunders P et al (2023) Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med 11:45–54. https://doi.org/10.1016/S2213-2600(22)00359-9

    Article  CAS  PubMed  Google Scholar 

  32. Sem M, Molberg O, Lund MB, Gran JT (2009) Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology 48:968–971. https://doi.org/10.1093/rheumatology/kep157

    Article  CAS  PubMed  Google Scholar 

  33. Aggarwal R, Bandos A, Reed AM et al (2014) Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 66:740–749. https://doi.org/10.1002/art.38270

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Andersson H, Sem M, Lund MB et al (2015) Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology 54:1420–1428. https://doi.org/10.1093/rheumatology/kev004

    Article  CAS  PubMed  Google Scholar 

  35. Oldroyd AGS, Lilleker JB, Amin T et al (2022) British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology 61:1760–1768. https://doi.org/10.1093/rheumatology/keac115

    Article  PubMed  PubMed Central  Google Scholar 

  36. Fujisawa T (2021) Management of myositis-associated interstitial lung disease. Medicina. https://doi.org/10.3390/medicina57040347

    Article  PubMed  PubMed Central  Google Scholar 

  37. Sacco KA, Abraham RS (2018) Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution. Immunotherapy 10:713–728. https://doi.org/10.2217/imt-2017-0178

    Article  CAS  PubMed  Google Scholar 

  38. Roberts DM, Jones RB, Smith RM et al (2015) Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. J Autoimmun 57:24–29. https://doi.org/10.1016/j.jaut.2014.11.004

    Article  CAS  PubMed  Google Scholar 

  39. López J, Merino L, Piris L et al (2019) Rituximab induces a lasting, non-cumulative remodelling of the B-cell compartment. Clin Exp Rheumatol 37:615–622

    PubMed  Google Scholar 

  40. Duarte AC, Cordeiro A, Fernandes BM et al (2019) Rituximab in connective tissue disease-associated interstitial lung disease. Clin Rheumatol 38:2001–2009. https://doi.org/10.1007/s10067-019-04557-7

    Article  PubMed  Google Scholar 

  41. Oddis CV, Aggarwal R (2018) Treatment in myositis. Nat Rev Rheumatol 14:279–289. https://doi.org/10.1038/nrrheum.2018.42

    Article  CAS  PubMed  Google Scholar 

  42. Robles-Perez A, Dorca J, Castellví I et al (2020) Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data. Rheumatol Int 40:719–726. https://doi.org/10.1007/s00296-020-04545-0

    Article  CAS  PubMed  Google Scholar 

  43. Xu L, Wang F, Luo F (2022) Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis. Front Pharmacol 13:1019915. https://doi.org/10.3389/fphar.2022.1019915

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Atienza-Mateo B, Remuzgo-Martínez S, Prieto-Peña D et al (2020) Rituximab in the treatment of interstitial lung disease associated with autoimmune diseases: experience from a single referral center and literature review. J Clin Med Res. https://doi.org/10.3390/jcm9103070

    Article  Google Scholar 

  45. Hervier B, Uzunhan Y (2019) Inflammatory myopathy-related interstitial lung disease: from pathophysiology to treatment. Front Med 6:326. https://doi.org/10.3389/fmed.2019.00326

    Article  Google Scholar 

  46. Jeganathan N, Sathananthan M (2020) Connective tissue disease-related interstitial lung disease: prevalence, patterns, predictors, prognosis, and treatment. Lung 198:735–759. https://doi.org/10.1007/s00408-020-00383-w

    Article  PubMed  Google Scholar 

  47. Cyclophosphamide and azathioprine vs tacrolimus in antisynthetase syndrome-related interstitial lung disease—full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03770663. Accessed 14 Mar 2023

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology and Clinical Immunology, Faculty of Medicine, Clinical Hospital Center Rijeka, University of Rijeka, Rijeka, Croatia

    Tatjana Zekić

Authors
  1. Tatjana Zekić
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TZ has designed the work and revised it critically for important intellectual content and decided on the final version to be published.

Corresponding author

Correspondence to Tatjana Zekić.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zekić, T. Rituximab as the first-line therapy in anti-synthetase syndrome-related interstitial lung disease. Rheumatol Int 43, 1015–1021 (2023). https://doi.org/10.1007/s00296-023-05302-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-023-05302-9

Keywords

Search

Navigation